AZD-103 to get 2nd Phasell Trial ....H2/08
Elan CEO said at the JP Morgan that ELND005/AZD-103 will be getting a second Phase11 Trial started targeting Early Alzheimers......perhaps starting H2 of this year.
Can't help but think that all the work done by Selkoe , Walsh. Shankar. Townsend etc. went into this decision. Shankar et al 2007 showed that Scyllo-Inositol Reversed Congnitive Impairment associated with the Toxicity that the Beta-Amyloid Oligomers, specifically Dimers and Trimers have on the synapse and associated Dendritic Spine Loss. They also showed that monomers had no such effect. This is related to very very early Alzheimers before any plaques are seen......when the memory starts to go!
I wonder if MCI will be the target or Early Alzheimers .....or Both!!
Hmmmmmmmm.......
GPP all!!